Wire · opportunities
Abbott rolls out SimpleScreen colorectal cancer blood test developed by Freenome
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Abbott has begun rolling out the SimpleScreen colorectal cancer blood test developed by Freenome, following FDA approval. The blood test complements Abbott's existing stool-based Cologuard Plus test and aims to increase colorectal cancer screening rates among adults 45 and older in the U.S.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 30 Sep 2026 and 2 Oct 2026.
◆ ◆ The Wire takeaway
Blood-based colorectal screening has moved from approval to market rollout, opening a direct opportunity to reach patients who avoid stool tests or colonoscopies. You should engage healthcare partners to integrate blood testing as a follow-up or alternative screening option to broaden patient access.
◆ Coverage
4 sources · first reported 30 Sep 2026 · latest 2 Oct 2026
◆ Related on Wire
◆ Topics